ERBB2 and non-small cell lung carcinoma: Other strategies are also assessed in clinical trials, including antibody-drug conjugates [e.g., ado-trastuzumab emtansine (T-DM1)] designed to target HER2 and release a cytotoxic drug in NSCLC patients with HER2 mutations.